C
Cingulate Inc. (CING)
NCM – Real vaqt narxi. Valyuta: USD
5.16
-0.04 (-0.77%)
Bozor ochiq: Aug 12, 2026, 2:29 PM EDT
5.12
-0.08 (-1.54%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
5.16
-0.04 (-0.77%)
Bozor ochiq: Aug 12, 2026, 2:29 PM EDT
5.12
-0.08 (-1.54%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Cingulate Inc., biofarmatsevtika kompaniyasi, Amerika Qo'shma Shtatlarida diqqat etishmasligi/giperaktivlik buzilishi (DEHB) va tashvishlarni davolash uchun o'zining dori vositalarini yetkazib berish platformasi texnologiyasidan foydalangan holda farmatsevtika mahsulotlarini ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodi CTx-1301 (deksmetilfenidat) bo'lib, u bolalar, o'smirlar va kattalardagi DEHBni davolash uchun 3-bosqichli klinik sinovlarda. Shuningdek, u tashvishlarni davolash uchun formulasi ishlab chiqilayotgan CTx-2103 (buspiron)ni ishlab chiqadi. Bundan tashqari, kompaniya DEHBni davolash uchun CTx-1302 (dekstroamfetamin) uchun klinik rejasini boshlashni rejalashtirmoqda. Cingulate Inc. 2012-yilda tashkil etilgan va uning shtab-kvartirasi Kanzas-Siti, Kanzasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer |
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Chairman of the Board |
| Mr. Downey Bryan Wade | Executive VP & Chief Commercial Officer |
| Mr. Thomas Dalton | Vice President of Investor & Public Relations |
| Ms. Jennifer L. Callahan CPA | Executive VP, CFO & Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-07-23 | 8-K | form8-k.htm |
| 2026-07-15 | S-8 | forms-8.htm |
| 2026-07-14 | 8-K | form8-k.htm |
| 2026-07-02 | 8-K | form8-k.htm |
| 2026-06-16 | 8-K | form8-k.htm |
| 2026-06-02 | 8-K | form8-k.htm |
| 2026-05-29 | DEFA14A | formdefa14a.htm |
| 2026-05-29 | DEF 14A | formdef14a.htm |
| 2026-05-29 | ARS | formars.pdf |
| 2026-05-19 | 8-K | form8-k.htm |